Mario R Cornejo-Olivas1, Luis Torres2, Ignacio F Mata3, Pilar Mazzetti4, Diana Rivas5, Carlos Cosentino2, Miguel Inca-Martinez4, Juan M Cuba2, Cyrus P Zabetian6, James B Leverenz7. 1. Northern Pacific Global Health Research Fellows Training Consortium, Bethesda, MD, USA; Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru. 2. Movement Disorders Unit, Instituto Nacional de Ciencias Neurologicas, Lima, Peru. 3. Geriatric Research Education and Clinical Center, VA Puget Sound Health Care System, USA; Department of Neurology, University of Washington, Seattle, WA, USA. 4. Neurogenetics Research Center, Instituto Nacional de Ciencias Neurologicas, Lima, Peru. 5. Neuropathology Department, Instituto Nacional de Ciencias Neurologicas, Lima, Peru. 6. Geriatric Research Education and Clinical Center, VA Puget Sound Health Care System, USA; Parkinson's Disease Research Education and Clinical Center, VA Puget Sound Health Care System, USA; Department of Neurology, University of Washington, Seattle, WA, USA. 7. Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA. Electronic address: leverej@ccf.org.
Abstract
BACKGROUND: Mutations in PARK2 result in autosomal recessive young onset Parkinson's disease (YOPD). Although there have been a number of reports on the clinical characteristics of PARK2-related PD, there is limited information available on the associated neuropathologic changes. DESIGN: We describe the clinical and pathological characteristics of a Peruvian family with YOPD. The proband and one unaffected sibling were screened for PARK2 dosage and point mutations. One affected sibling had detailed neuropathologic examination. SETTING: Instituto Nacional de Ciencias Neurologicas (INCN) in Lima, Peru. RESULTS: The proband and two of her four siblings developed YOPD and both parents were unaffected. The clinical course has been characterized by akinetic-rigid parkinsonism predominantly affecting the lower limbs and dyskinesias. Analysis of PARK2 showed that the proband is compound heterozygous for a novel acceptor splice site mutation in intron 5 (IVS5-1G>A) and an exon 7 deletion. Neuropathologic assessment of an affected sibling revealed severe neuronal loss in the substantia nigra (SN) and loss of tyrosine hydroxylase immunopositive fibers in the striatum. No Lewy body pathology was observed using standard histology or immunohistochemistry for α-synuclein. CONCLUSIONS: Consistent with most neuropathologic reports of patients with PARK2 mutations, we did not observe Lewy body inclusions, despite marked SN degeneration and severe dopaminergic denervation of the striatum. These data describe a novel splice site mutation and further extend the clinicopathological characterization of PARK2-associated PD.
BACKGROUND: Mutations in PARK2 result in autosomal recessive young onset Parkinson's disease (YOPD). Although there have been a number of reports on the clinical characteristics of PARK2-related PD, there is limited information available on the associated neuropathologic changes. DESIGN: We describe the clinical and pathological characteristics of a Peruvian family with YOPD. The proband and one unaffected sibling were screened for PARK2 dosage and point mutations. One affected sibling had detailed neuropathologic examination. SETTING: Instituto Nacional de Ciencias Neurologicas (INCN) in Lima, Peru. RESULTS: The proband and two of her four siblings developed YOPD and both parents were unaffected. The clinical course has been characterized by akinetic-rigid parkinsonism predominantly affecting the lower limbs and dyskinesias. Analysis of PARK2 showed that the proband is compound heterozygous for a novel acceptor splice site mutation in intron 5 (IVS5-1G>A) and an exon 7 deletion. Neuropathologic assessment of an affected sibling revealed severe neuronal loss in the substantia nigra (SN) and loss of tyrosine hydroxylase immunopositive fibers in the striatum. No Lewy body pathology was observed using standard histology or immunohistochemistry for α-synuclein. CONCLUSIONS: Consistent with most neuropathologic reports of patients with PARK2 mutations, we did not observe Lewy body inclusions, despite marked SN degeneration and severe dopaminergic denervation of the striatum. These data describe a novel splice site mutation and further extend the clinicopathological characterization of PARK2-associated PD.
Authors: M Farrer; P Chan; R Chen; L Tan; S Lincoln; D Hernandez; L Forno; K Gwinn-Hardy; L Petrucelli; J Hussey; A Singleton; C Tanner; J Hardy; J W Langston Journal: Ann Neurol Date: 2001-09 Impact factor: 10.422
Authors: E Lohmann; S Thobois; S Lesage; E Broussolle; S Tezenas du Montcel; M-J Ribeiro; P Remy; A Pelissolo; B Dubois; L Mallet; P Pollak; Y Agid; A Brice Journal: Neurology Date: 2008-11-05 Impact factor: 9.910
Authors: Louis C Tan; Caroline M Tanner; Rong Chen; Piu Chan; Matthew Farrer; John Hardy; J William Langston Journal: Mov Disord Date: 2003-07 Impact factor: 10.338
Authors: James B Leverenz; Ronald Hamilton; Debby W Tsuang; Aimee Schantz; Darcy Vavrek; Eric B Larson; Walter A Kukull; Oscar Lopez; Douglas Galasko; Eliezer Masliah; Jeffrey Kaye; Randall Woltjer; Christopher Clark; John Q Trojanowski; Thomas J Montine Journal: Brain Pathol Date: 2008-01-29 Impact factor: 6.508
Authors: Aida M Bertoli-Avella; José L Giroud-Benitez; Ali Akyol; Egberto Barbosa; Onno Schaap; Herma C van der Linde; Emilia Martignoni; Leonardo Lopiano; Paolo Lamberti; Emiliana Fincati; Angelo Antonini; Fabrizio Stocchi; Pasquale Montagna; Ferdinando Squitieri; Paolo Marini; Giovanni Abbruzzese; Giovanni Fabbrini; Roberto Marconi; Alessio Dalla Libera; Giorgio Trianni; Marco Guidi; Antonio De Gaetano; Gustavo Boff Maegawa; Antonino De Leo; Virgilio Gallai; Giulia de Rosa; Nicola Vanacore; Giuseppe Meco; Cornelia M van Duijn; Ben A Oostra; Peter Heutink; Vincenzo Bonifati Journal: Mov Disord Date: 2005-04 Impact factor: 10.338
Authors: Sarah Teixeira Camargos; Leonardo Oliveira Dornas; Parastoo Momeni; Andrew Lees; John Hardy; Andrew Singleton; Francisco Cardoso Journal: Mov Disord Date: 2009-04-15 Impact factor: 10.338
Authors: Ignacio F Mata; Marie Y Davis; Alexis N Lopez; Michael O Dorschner; Erica Martinez; Dora Yearout; Brenna A Cholerton; Shu-Ching Hu; Karen L Edwards; Thomas D Bird; Cyrus P Zabetian Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2016-04-25 Impact factor: 3.568
Authors: Tariq Alafifi; Abdul Rahim Ali Bakhsh; Mahfoud Elbashari; Mohamed El Hosseiny Abouelnaga; Ahmed Medhat Eldimllawi Journal: Oman Med J Date: 2020-06-30
Authors: Heinner Guio; Julio A Poterico; Kelly S Levano; Mario Cornejo-Olivas; Pilar Mazzetti; Gioconda Manassero-Morales; Manuel F Ugarte-Gil; Eduardo Acevedo-Vásquez; Milagros Dueñas-Roque; Alejandro Piscoya; Ricardo Fujita; Cesar Sanchez; Sandro Casavilca-Zambrano; Luis Jaramillo-Valverde; Yasser Sullcahuaman-Allende; Juan M Iglesias-Pedraz; Hugo Abarca-Barriga Journal: Mol Genet Genomic Med Date: 2018-11 Impact factor: 2.183
Authors: Valentina Nicoletti; Giovanni Palermo; Eleonora Del Prete; Michelangelo Mancuso; Roberto Ceravolo Journal: Front Cell Dev Biol Date: 2021-04-01
Authors: Elif Irem Sarihan; Eduardo Pérez-Palma; Lisa-Marie Niestroj; Douglas Loesch; Miguel Inca-Martinez; Andrea R V R Horimoto; Mario Cornejo-Olivas; Luis Torres; Pilar Mazzetti; Carlos Cosentino; Elison Sarapura-Castro; Andrea Rivera-Valdivia; Elena Dieguez; Victor Raggio; Andres Lescano; Vitor Tumas; Vanderci Borges; Henrique B Ferraz; Carlos R Rieder; Artur F Schumacher-Schuh; Bruno L Santos-Lobato; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio; Francisco Lopera; Sonia Moreno; Pedro Chana-Cuevas; William Fernandez; Gonzalo Arboleda; Humberto Arboleda; Carlos E Arboleda-Bustos; Dora Yearout; Cyrus P Zabetian; Timothy A Thornton; Timothy D O'Connor; Dennis Lal; Ignacio F Mata Journal: Mov Disord Date: 2020-11-05 Impact factor: 10.338